Stock PHAT PHATHOM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Real-time Estimate Cboe BZX
Other stock markets
 15:16:44 2024-05-10 EDT 		5-day change 1st Jan Change
9.425 USD -6.59% Intraday chart for Phathom Pharmaceuticals, Inc. -5.93% +3.45%
05-09 Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09 Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Phathom Pharmaceuticals : First Quarter 2024 Earnings Call – May 2024
PU
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
GL
Phathom Pharmaceuticals : Corporate Overview – April 2024
PU
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GL
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AQ
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, 'VOQUEZNA Can Kick Some Acid'
AQ
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
GL
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
GL
Phathom Pharmaceuticals Announces VOQUEZNA Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
AQ
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
GL
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
AQ
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
AQ
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
GL
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
AQ
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
GL
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
AQ
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHAT Stock
  4. News Phathom Pharmaceuticals, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW